CE-224535 is a novel and selective P2X7 receptor antagonist that can be potentially used for the treatment of rheumatoid arthritis and osteoarthritis. Clinical trials showed that CE-224,535 was not efficacious as compared with placebo, for the treatment of RA in patients with an inadequate response to MTX. CE-224,535 demonstrated an acceptable safety and tolerability profile.

PF-03709270 (also known as Sulopenem etzadroxil; PF 03709270) is a novel, potent and orally bioavailable ester prodrug of sulopenem, with broad-spectrum antibacterial activity against most gram-positive and gram-negative bacteria. Sulopenem etzadroxil is a penem antibiotic agent that was more stable than imipenem against swine and human dehydropeptidase-Is. Sulopenem is one of the antibiotics that do […]

Dolcanatide (formerly SP-333; SP333; SP 333) is the second uroguanylin analog currently being developed for ulcerative colitis by Synergy Pharmaceuticals which is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. Analogs of uroguanylin, a naturally occurring human GI peptide, have the potential for the treatment of functional GI disorders […]

BMS 433771 is a novel and potent inhibitor of RSV (respiratory syncytial virus) replication in vitro. It demonstrate excellent potency against multiple laboratory and clinical isolates of both A and B RSV with an average EC of 20nM

Mc-Val-Cit-PAB-Cl is a novel and potent ADC linker

m-PEG25-NHS ester is a novel and potent PROTAC linker

m-PEG11-OH is a novel and potent PROTAC linker

SPDP-PEG24-acid is a novel and potent PROTAC linker

Quetiapine sulfoxide dihydrochloride (Quetiapine S-oxide 2HCl) is a major metabolite of Quetiapinem, which is a 2nd-generation antipsychotic acting as a 5-HT receptor agonist and a dopamine receptor antagonist.

D-Erythrose 4-phosphate sodium is a novel and potent phosphate